SNSS:NASDAQ

Sunesis Pharmaceuticals Inc.

Sunesis Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The company has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer.

Expert Comments:

Hartaj Singh, BTIG Research (6/17/15)
"Sunesis Pharmaceuticals Inc. recently presented abstracts at both ASCO 2015 and at EHA 2015 in Vienna. The data presented by Sunesis underlies our thesis that vosaroxin is an active compound in acute myeloid leukemia where there is a large unmet need. . .going into the FDA meeting, we believe that current risk/reward is well-balanced. We assume a 60% chance of FDA giving a favorable review (versus oncology phase 3 trials that progress to NDA/BLA ~45% of the time) with a potential 30% upside move on NDA filing and a 45% downside move if not."

"Sunesis Pharmaceuticals Inc. has been developing Qinprezo (vosaroxin) in acute myeloid leukemia (AML) for a very long time now. The company showed some intriguing Phase 2 data for the therapy, and ran a somewhat large Phase 3 study, with more than 700 patients, called VALOR. . .the data did not reach statistical significance with regard to overall survival, which was the primary endpoint. But I think Qinprezo definitely falls into the category of questioning what's left following bad data. . .the data did show a significant survival benefit when censored for stem cell transplant in AML patients. . .additionally, the intriguing component of the study, in my belief, is that a nice survival benefit was seen in patients 60 years and older, and these data were highlighted at the recent American Society of Clinical Oncology (ASCO) conference. . ." read more >

Joseph Pantginis, ROTH Capital Partners (6/15/15)
"Sunesis Pharmaceuticals Inc.'s two European Hematology Association presentations provide subgroup analyses by (a) cytogenetic risk, in which only the intermediate group achieved a statistically significant improvement in complete response rate and (b) by disease status, in which refractory and early relapse patients achieved significant improvements in overall survival, complete response, event-free survival and leukemia-free survival. We believe these could be meaningful to regulators and await announcement on the outcomes of discussions with the U.S. Food and Drug Administration and the European Medicines Agency."

Mara Goldstein, Cantor Fitzgerald (6/12/15)
"We maintain a Buy rating and $4 price target ahead of Sunesis Pharmaceuticals Inc.'s poster presentations of VALOR data at the European Hematology Association's annual meeting, as well as pending news regarding the status of a new drug application (NDA) filing for Qinprezo for acute myelogenous leukemia. We base this on our view that an NDA for Qinprezo will be filed, and that will allow the shares to be revalued."

David Nierengarten, Wedbush (6/12/15)
"Sunesis Pharmaceuticals Inc. presented post hoc subgroup analysis data from its Phase 3 VALOR study of vosaroxin in relapsed/refractory acute myelogenous leukemia (AML) patients (n=711) at the European Hematology Association meeting today. . .the data reinforce that vosaroxin has a potential treatment role for AML."

Matthew Andrews, Wells Fargo Securities (6/12/15)
"Additional subgroup analyses of Sunesis Pharmaceuticals Inc.'s VALOR are beginning to suggest the most favorable risk/benefit appears to be in refractory/early relapse patients greater than 60 years of age (n=451). . .the company's management noted it is on track for 'midyear' discussions with the U.S. Food and Drug Administration and the European Medicines Agency, which will help guide potential next regulatory steps, which we believe could lead to possibly submissions later in the summer."

Management Q&A: View From the Top
Daniel Swisher, Jr.
Daniel N. Swisher Jr., president and CEO of Sunesis Pharmaceuticals Inc., describes how his company is making clinical progress toward developing a new treatment for acute myelogenous leukemia, and how the broad Sunesis kinase inhibitor portfolio provides additional firepower against other cancers.
read more >

More Expert Comments

Experts Commenting on This Company

Matthew Andrews, Equity Senior Analyst – Wells Fargo Securities
Reni Benjamin, Senior Biotechnology Analyst – H.C. Wainwright & Co.
Mara Goldstein, Senior Analyst – Cantor Fitzgerald
David Nierengarten, Research Analyst – Wedbush
Joseph Pantginis, Senior Analyst – ROTH Capital Partners
Hartaj Singh, Biotechnology Analyst – BTIG Research
George Zavoico, Senior Equity Analyst – JonesTrading International Services LLC

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Investing Highlights
 
Totality of VALOR data shows compelling risk-benefit trade-off in disease with significant unmet need
 
Relapsed/refractory AML is a significant commercial opportunity with no approved agents
 
Our kinase inhibitor pipeline is poised to progress to the clinic in 2015 and 2016
catalyst Calendar
Sunesis Pharmaceuticals Inc. Content